216.73.216.231===--UPDATE `0-usmeigara` SET site='',name='',jigyoyoyaku='',sijyo='',gyosyu='',honten='',industry='',sector='',haishi='',keyword='' where code = 'avir'---select * from `0-usmeigara` WHERE code='avir'
aaアテア　ファーマシューティカルズ

avir
銘柄登録／業種登録　関連銘柄専用コメ／リスト／日本株
・

url
name
code
業種
htmldesc　分割：<split>
ウイルス感染症に苦しむ患者の抗ウイルス治療薬の発見、開発、および商業化に焦点を当てた臨床段階のバイオ医薬品会社であるAtea Pharmaceuticals、Inc.。同社はまた、デング熱の治療と予防のためのフェーズII臨床試験中の薬物であるAT-752を開発しています。AT-281は、デング熱、黄熱病、ジカウイルスを含むRNAウイルス感染の治療または予防のための薬学的に許容される塩、および慢性HCV感染の治療のための治療NS5A阻害剤であるルザスビルです。
keyword
sijyo
honten
industry
sector
haishi

事業内容も含めて検索

日本語に翻訳して１５０文字程度で要約を。語尾は「している」等の常体で
「Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.」